Ventus Therapeutics has begun trials on VENT-03, an oral drug designed to block cGAS, marking a pioneering approach in this category.

Alvotech, a global biopharma company specializing in biosimilars, reported positive early results from a key trial of AVT06, its candidate similar to Eylea® (aflibercept).

OBI Pharma announced the FDA has approved its investigational new drug application for OBI-992, allowing the start of a phase 1/2 clinical trial to evaluate their novel TROP2-targeted antibody-drug conjugate for cancer treatment.

Belief BioMed Group announced the start of patient treatment in a major BBM-H803 study. This gene therapy aims to treat hemophilia A and is independently developed by Belief BioMed.

Sciwind Biosciences Reveals Encouraging Preliminary Outcomes from a Final-Stage Study of Ecnoglutide (XW003), an Extended-Duration GLP-1 Mimetic with Selective cAMP Pathway Activation, in Chinese Adults Suffering from Type 2 Diabetes.

Coherus BioSciences, Inc. has recently declared that their product, LOQTORZI™ (toripalimab-tpzi), can now be acquired from certain specialty distribution channels within the U.S. market.

Atom Bioscience, a biotech company specializing in innovative therapies for inflammation and metabolic diseases, announced FDA approval for the Phase 1 trial of its new drug, ABP-745.

Ubix Therapeutics Granted Green Light from FDA for Initial Clinical Trial of Oral Drug UBX-303-1, a BTK Inhibitor Aimed at Treating Resistant B-Cell Cancers.

NKGen Biotech, Inc. declares the commencement of treatment in its initial participant within a Phase 1/2a Study using its own SNK01, aimed for moderate Alzheimer's Disease.

NeuroBo Pharma has filed an Investigational New Drug request with the FDA, seeking approval to commence a Phase 1 trial on compound DA-1726 aimed at combating obesity.

Clover Biopharmaceuticals reports positive initial findings from a phase I trial evaluating SCB-219M, an advanced bispecific Fc-fusion TPO-RA protein developed with CHO cell systems, focusing on safety, efficacy, and pharmacokinetics.

Innovent and Xuanzhu Initiate Joint Study Exploring Dual Treatment Approach with Sintilimab (PD-1 Blocker) Plus a New ADC Drug for Progressive Solid Cancers in China.